Humira biosimilars earn spot on OptumRx’s formulary

OptrumRx, UnitedHealth’s pharmacy benefit manager, will keep AbbVie’s best-selling rheumatoid arthritis drug Humira on its formulary in 2023 alongside three competing biosimilar versions set to debut next year, Bloomberg reported Nov. 15.

Advertisement
By: Mackenzie Bean

Heather Cianfrocco, CEO of Optum Rx, disclosed the decision at the HLTH conference held Nov. 15 in Las Vegas. OptumRx is the nation’s third largest PBM and the first to disclose how it will handle new competition for Humira. 

The PBM said it will not prefer one version of the drug over another in its formulary. 

Humira has generated nearly $200 billion in sales for AbbVie. The company’s stock rose 1.7 percent upon news of OptumRx’s decision.

The critical balance: How hospital medicine aligns patient acuity and system capacity to protect access to care

Recommended Whitepaper

Advertisement

Next Up in Pharmacy

  • 75 drugs currently in shortage: FDA

    The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

    By: Mackenzie Bean

  • 6 recent updates on GLP-1 drugs

    From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

    By: Ella Jeffries

  • 73 drugs lost exclusivity in 2025

    In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

    By: Paige Twenter
Advertisement

Comments are closed.